Scarica l'app Stockscreener
14.07
35.94%
-7.895
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
What analysts say about Sarepta Therapeutics Inc. stockFree Stock Selection - Autocar Professional
Sarepta Therapeutics Inc. Stock Analysis and ForecastConsistently superior profits - Jammu Links News
This Gene Therapy Maker Refuses to Halt Shipments After Patient Deaths - Men's Journal
What drives Sarepta Therapeutics Inc. stock priceAccelerated wealth expansion - Autocar Professional
Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline - Hoodline
Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths - WTOP
Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths - Yahoo Finance
Gene Therapy Maker Sarepta Tells FDA It Won't Halt Shipments Despite Patient Deaths - U.S. News & World Report
Sarepta Therapeutics lays off 500 employees amid FDA investigation, including 80 in Columbus - nbc4i.com
Sarepta to continue Elevidys shipments despite FDA request to halt - Seeking Alpha
Securities Fraud Litigation and Shareholder Returns: A Strategic Evaluation of Sarepta Therapeutics' ELEVIDYS Case - AInvest
M&T Bank Corp Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Sarepta Therapeutics: A Sell Signal Amid Safety Crises and Existential Risks - AInvest
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down Following Analyst Downgrade - Defense World
Sarepta Therapeutics (NASDAQ:SRPT) Reaches New 52-Week Low Following Analyst Downgrade - Defense World
Sarepta Therapeutics laying off nearly 500 employees, including 80 in Franklin County - 10TV
Sarepta CEO: ‘We Have, I Believe, a Very Laudable History of Being Extraordinarily Transparent’ - MedCity News
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. - GlobeNewswire
Exclusive: Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys - Reuters
Is Sarepta Therapeutics Inc. a good long term investmentOutstanding capital growth - Jammu Links News
Securities Fraud Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT)Levi & Korsinsky Reminds Investors of August 25, 2025 - ACCESS Newswire
Sarepta receives FDA request to halt ELEVIDYS shipments for some patients - StreetInsider
Sarepta Says Another Patient Died After Receiving Gene Therapy - Bloomberg
FDA Shuts Down Sarepta's Distribution of Gene Therapy Elevidys Following Patient Deaths - NeurologyLive
Sarepta Therapeutics Provides Statement on ELEVIDYS - Sarepta Therapeutics
Gene-therapy company to eliminate 21 Durham employees as part of major restructuring - WRAL.com
HHS Says FDA Requests Sarepta Therapeutics Suspend Distribution Of Elevidys And Places Clinical Trials On Hold For Multiple Gene Therapy Products Following 3 Deaths - TradingView
FDA prepares to ask Sarepta Therapeutics to stop all shipments of Duchenne muscular dystrophy therapy - The Boston Globe
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Exclusive-US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says - MarketScreener
Exclusive: US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says - Reuters
Sarepta Therapeutics laying off 80 employees in Ohio - WTTE
Sarepta Therapeutics crisis is huge blow to Duchenne families, company - statnews.com
Major biotech stock tumbles 35 percent after major rare disease setback - TheStreet
Sarepta Crashes Almost 40% On A Damning Move From The FDA - Investor's Business Daily
Elevidys' future said to be on ice after Sarepta reports patient death from separate gene therapy - FirstWord Pharma
FDA to Ask Sarepta to Stop Shipping Muscular Dystrophy Drug Elevidys - The New York Times
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Investors Urged to Contact Levi & Korsinsky for Information Before August 25, 2025Sarepta Therapeutics, Inc. (SRPT) - TradingView
Sarepta Stock (SRPT) Crashes 37% as FDA Scrutiny Mounts Over Gene Therapy Deaths - TipRanks
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Announces Third Death -- Contact BFA Law by the August 25 Class Action Deadline - GlobeNewswire
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Announces Third Death -- Contact BFA Law by the August 25 Class Action Deadline - GlobeNewswire Inc.
Baird downgrades Sarepta Therapeutics stock rating on Elevidys safety concerns - Investing.com
FDA mulls Elevidys market withdrawal following 3rd death after Sarepta gene therapy - Fierce Pharma
Sarepta shares plunge 30% as future of its gene therapy appears at risk - MSN
Sarepta Shares Crash on Report That FDA Will Ask It to Stop Shipping Drug - Barron's
Sarepta Craters as FDA Considers Requesting Halt to Elevidys Shipments - BioSpace
FDA to ask Sarepta to stop shipping Duchenne gene therapy - BioPharma Dive
Sarepta: Despite Restructuring, Downgrading To Sell After Latest Developments (SRPT) - Seeking Alpha
Baird Downgrades Sarepta Therapeutics (SRPT) to Neutral, 'Transparency Issues and Elevidys Uncertainty' - StreetInsider
Strategic Restructure and ELEVIDYS Label Update Call (NASDAQ:SRPT) - Seeking Alpha
Sarepta falls as FDA mulls Elevidys' future (update) (SRPT) - Seeking Alpha
Exclusive: US FDA to request Sarepta to stop all shipments of gene therapy Elevidys, source says - Reuters
Sarepta shares plunge 40% as future of its gene therapy appears at risk - CNBC
Sarepta Therapeutics stock hits 52-week low at 16.87 USD By Investing.com - Investing.com South Africa
Sarepta share price drops again after third gene therapy death - Yahoo Finance
FDA asks Sarepta to stop shipping gene therapy after patient deaths. Sarepta says no. - The Business Journals
Sarepta Therapeutics stock hits 52-week low at 16.87 USD - Investing.com Australia
0.59%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):